GPGulseren Pekbak

Gulseren Pekbak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gulseren Pekbak has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The spectrum of airway dysfunction in asthma: a focus on small airways from the Turkish adult asthma registry

    by Sinem İnAn, Can Sevinç, Funda Seher Özalp Ateş, Eylem Sercan Özgür, Serap Argun Barış, Murat Kavas, Şengül Beyaz, Demet Polat Yuluğ, Yavuz Havlucu, Özcan Gül, et al.

  • Distinct characteristics of asthma overlap phenotypes: Insights from the Turkish adult asthma registry

    by Secil Kepil Ozdemir, Bilun Gemicioglu, Fusun Yildiz, Serhat Hayme, Gulistan Alpagat, Nurgul Bozkurt, Ismet Bulut, Munevver Erdinc, Gul Karakaya, Metin Keren, et al.

    Considerable overlaps exist between asthma phenotypes and the clinical significance of these overlaps remains undetermined. The objective of this study is to analyze the characteristics of asthma overlap phenotypes using data from the Turkish Adult Asthma Registry (TAAR). This cross-sectional registry study included 2053 adult patients (74.8% female) with asthma. Overall, 39.3% (n = 697) had allergic-eosinophilic (AE), 26.0% (n = 461) had allergic-non-eosinophilic (ANE), 21.3% (n = 377) had non-allergic-eosinophilic (NAE), and 13.4% (n = 237) had non-allergic-non-eosinophilic (NANE) asthma. Severe asthma exacerbations and emergency department (ED) visits were more frequent in the AE (28.3%, 31.2%, respectively) and NAE groups (36.0%, 34.0%, respectively) than in the ANE (14.3%, 20.6%, respectively) and NANE groups (12.6%, 16.7%, respectively) (p < 0.001). FEV1 values were significantly lower in the AE group than in the ANE and NANE groups (p < 0.001, p = 0.048, respectively) and in the NAE group than in the ANE group (p < 0.001). Risk factors for poor asthma control included living in rural areas, asthma-related ED visits, FEV1 < 60% in the NAE; being overweight, chronic rhinosinusitis, oral corticosteroids use, age < 40 years in the NANE; FEV1 < 80% in the AE; and severe asthma exacerbations, ED visits for AE and ANE groups. The considerable overlap between allergic and eosinophilic asthma phenotypes has clinical implications as increased rates of asthma exacerbations and healthcare utilization. The clinical heterogeneity among asthma phenotypes based on a single biomarker highlights the importance of multidimensional asthma phenotyping.


  • Open Access

    What Does Radiologic Assessment Contribute to Asthma: A Subanalysis of the Turkish Adult Asthma Registry

    by Deniz Kizilirmak, Oguz Uzun, Derya Gokmen, Omur Aydın, Ilknur Basyigit, Adile Berna Dursun, Ilkay Koca Kalkan, Sumeyra Alan Yalim, Tugce Yakut, Gozde Koycu Buhari, et al.

    Objectives: It is aimed to assess how physicians use chest imaging in asthma and the relationship between the pathological findings and related disease characteristics in the radiological imaging of asthmatic patients. Background: The daily practice of imaging and its contribution to the management of asthma are not well defined. It is common to use radiological imaging to investigate pathologies that cause respiratory symptoms and to evaluate differential diagnoses in asthma patients. In this study, as a subanalysis of the Turkish Adult Asthma Registry, radiological findings and outcomes of asthmatic patients were examined. Methods: Between March 2018 and March 2022, the data of asthma patients in 36 secondary and tertiary health care centers was recorded using a web-based application. Patients with chest X-ray, computed thorax tomography, and paranasal sinus tomography data in the asthma database were statistically evaluated for sub-analysis. Results: The study included 2053 patients. Chest X-rays were taken in the majority of the cases (n:1739; 84.7%). Computed thorax tomography was performed in 869 (42.3%) patients and paranasal sinus tomography in 388 (18.9%) patients. The most common pathological findings on chest X-rays of asthmatic patients were increased bronchovascular branching and dirty lung appearance, whereas they were linear atelectasis, and bronchial wall thickening on computed thorax tomography bronchiectasis. Soft tissue in the sinuses and nasal polyps were the most common pathological findings in paranasal sinus tomography. Pathological findings were much more common in the radiological evaluations of patients with eosinophilic and allergic phenotypes and in patients with severe asthma. Conclusion: The radiological findings of asthma vary depending on the phenotype and severity of the disease. Patients with asthma, particularly those in the high-risk group, should be evaluated from a radiological perspective.

  • Factors influencing the prescription of add-on long-acting muscarinic antagonists in real-world asthma management: Insights from a national registry

    by Bilun Gemicioglu, Derya Gokmen, Ali Can, Can Sevinc, Ipek Kivilcim Oguzulgen, Sadan Soyyigit, Tugce Yakut, Yavuz Havlucu, Omur Aydin, Gozde Koycu Buhari, et al.


  • Picturing asthma in Turkey: results from the Turkish adult asthma registry

    by Gulfem Elif Celik, Omur Aydin, Derya Gokmen, Gozde Koycu Buhari, Zeynep Celebi Sozener, Bilun Gemicioglu, Ismet Bulut, Sengul Beyaz, Cihan Orcen, Secil Kepil Ozdemir, et al.

    National data on asthma characteristics and the factors associated with uncontrolled asthma seem to be necessary for every country. For this purpose, we developed the Turkish Adult Asthma Registry ...


  • Open Access

    Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab

    by Dane Ediger, Fatma Esra Günaydın, Müge Erbay, Gülseren Pekbak

    Omalizumab, a humanized monoclonal anti-IgE antibody, has largely demonstrated its efficacy in severe allergic asthma. There are limited data about the effectiveness of omalizumab in patients with non-atopic severe persistent asthma. In this study, we aimed to determine the effect of omalizumab in patients with non-atopic severe asthma and compare the data obtained with those in patients with allergic severe asthma. This study was an observational, retrospective, tertiary single-center study that assessed and compared the clinical outcome of adult patients with severe asthma (165 atopic and 41 non-atopic) who have been on omalizumab for one year or longer between January 2008 and January 2020. Effectiveness was assessed by considering symptom scores (GINA symptom control score), daily systemic corticosteroids (SCS) dosage, blood eosinophil counts, pulmonary function, and number of severe exacerbations and hospitalizations within the last one year. Omalizumab exhibited significant improvement in the clinical status of non-atopic asthma patients as measured by GINA symptom score [decreased from 3.77 ± 0.63 to 1.36 ± 1.27 (p<0.001)], the number of emergency room visits for asthma [decreased from 11.25 ± 14.69 to 0.25 ± 0.55 (p<0.001)], and the number of hospitalizations [decreased from 1.17 ± 2.87 to 0.14 ± 0.36 (p= 0.036)]. These results were not significantly different from those obtained in allergic asthma patients. FEV1 improved significantly from 2.08 ± 0.86 to 2.14 ± 0.84 (p= 0.041) and oral corticosteroid doses decreased significantly from 1.67 ± 7.49 to 0.46 ± 2.74 (p= 0.015) in the only atopic group. Omalizumab, which is a proven and effective treatment option for allergic asthma, may also be an efficacious alternative option in non-atopic severe asthma.